EP2309995A1 - Formulation pharmaceutique pour la réduction de la pression artérielle pulmonaire - Google Patents

Formulation pharmaceutique pour la réduction de la pression artérielle pulmonaire

Info

Publication number
EP2309995A1
EP2309995A1 EP09777743A EP09777743A EP2309995A1 EP 2309995 A1 EP2309995 A1 EP 2309995A1 EP 09777743 A EP09777743 A EP 09777743A EP 09777743 A EP09777743 A EP 09777743A EP 2309995 A1 EP2309995 A1 EP 2309995A1
Authority
EP
European Patent Office
Prior art keywords
ambrisentan
micronized
hydrophilizing agent
pharmaceutical formulation
tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09777743A
Other languages
German (de)
English (en)
Inventor
Katrin Rimkus
Frank Muskulus
Sandra Brueck
Jana Paetz
Dunja Kotschenreuther
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ratiopharm GmbH
Original Assignee
Ratiopharm GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm GmbH filed Critical Ratiopharm GmbH
Publication of EP2309995A1 publication Critical patent/EP2309995A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Definitions

  • the invention relates to pharmaceutical formulations for pulmonary lowering of blood pressure containing micronized ambrisentan, preferably in the form of an intermediate together with a hydrophilicizing agent.
  • the invention further relates to processes for the preparation of pharmaceutical formulations containing micronized ambrisentan.
  • Ambrisentan is an endothelin receptor antagonist and is approved for the treatment of pulmonary hypertension (pulmonary hypertension). Ambrisentan displaces the endothelin-1, the strongest known endogenous antibody, as an antagonist
  • Endothelin 1 effect on, so that the vessels dilate and so through the
  • ambrisentan [INN] is (2S) -2- (4,6-dimethylpyrimidin-2-yl) oxy-3-methoxy-3,3-di (phenyl) propanoic acid.
  • the chemical structure of ambrisentan is shown in formula (1) below:
  • ambrisentan has been described by Riechers et al., J. Med. Chem. 39 (11), 2123 (1996) and in WO 96/1 1914, and results in a white, crystalline solid.
  • Ambrisentan is marketed under the trade name Volibris ® as film-coated tablets.
  • Volibris contains ambrisentan in crystalline form, whereby the tableting by means of
  • Replacement Blade produced by direct compression of "untreated” crystalline ambrisentan could be improved in terms of their bioavailability. Furthermore, it is problematic to realize with this method, a high drug content (eg 70%) in the tablet. Furthermore, it has been shown that with low active ingredient content (eg 15%), the uniformity of the active ingredient distribution (Content Unity) should be improved.
  • Object of the present invention was therefore to overcome the disadvantages mentioned above. It should provide the active ingredient in a form that has good flowability and good compression possible. The resulting tablets are said to have high hardness and low friability.
  • the active ingredient should be provided in a formulation that ensures good solubility with good storage stability at the same time. Furthermore, a camp stability of 12 months at 40 0 C and 75% humidity is to be achieved. After such storage, the impurities should be less than 2% by weight, in particular less than 1% by weight.
  • the active ingredient content can be varied over a wide range.
  • an active ingredient content of 10 to 70 wt .-% should be achievable.
  • the resulting tablet should have a particularly uniform distribution of active ingredient, in particular, the resulting tablet should have a uniform distribution of active ingredient at low drug levels (about 10 to 20 wt.%).
  • micronization of ambrisentan preferably by micronization and hydrophilization of ambrisentan, in particular by micronization, hydrophilization and wet granulation of ambrisentan.
  • the invention therefore micronized ambrisentan.
  • the invention further provides an intermediate containing micronised ambrisentan and a hydrophilizing agent.
  • the invention furthermore relates to processes for the preparation of micronized ambrisentan or of hydrophilized micronized ambrisentan in the form of the intermediate according to the invention.
  • the invention relates to pharmaceutical formulations containing the micronized ambrisentan according to the invention or the According to the invention, micronized and hydrophilic ambrisentan in the form of the intermediate.
  • the term “ambrisentan” comprises (2S) -2- (4,6-dimethylpyrimidin-2-yl) oxy-3-methoxy-3,3-di (phenyl) propanoic acid according to formula (1) above.
  • the term “ambrisentan” includes all pharmaceutically acceptable salts and solvates thereof.
  • the term “ambrisentan” is ambrisentan in crystalline form, i. preferably more than 90% by weight of the ambrisent used is in crystalline form, in particular 100%.
  • micronized ambrisentan in the context of this invention refers to particulate ambrisentan, which generally has an average particle diameter of from 0.1 to 200 .mu.m, preferably from 0.5 to 100 .mu.m, more preferably from 1 to 50 .mu.m, more preferably from 1.5 to 30 microns and especially from 2 to 20 microns or from 1.5 microns to 25 microns and in particular from 2 microns to 10 microns.
  • average particle diameter in the context of this invention refers to the D50 value of the volume-average particle diameter, which was determined by means of laser diffractometry.
  • a Mastersizer 2000 from Malvern Instruments was used for the determination (wet measurement, 2000 rpm, ultrasound 60 sec., Preferably shading 4 to 13%, preferably dispersion in liquid paraffin, evaluation by means of the Fraunhofer method).
  • the average particle diameter also referred to as the D50 value of the integral volume distribution, is defined in the context of this invention as the particle diameter at which 50% by volume of the particles have a smaller diameter than the diameter corresponding to the D50 value. Likewise, then 50% by volume of the particles have a larger diameter than the D50 value.
  • the D10 value of the integral volume distribution is defined as the particle diameter at which 10% by volume of the particles have a smaller diameter than the diameter which corresponds to the D10 value.
  • the D90 value of the integral volume distribution is defined as the particle diameter at which 90% by volume of the particles have a smaller diameter than the diameter corresponding to the D90 value.
  • the ambrisentan according to the invention is present in micronized and hydrophilized form, namely in the form of an intermediate which contains micronized ambrisentan and a hydrophilizing agent.
  • the intermediate according to the invention consists essentially of micronized ambrisentan and hydrophilizing agent. The term "essentially” indicates here indicates that possibly even small amounts of solvent etc. may be included.
  • hydrophilizing agent in the context of this invention is generally a substance which is capable of attaching to ambrisentan (chemically or physically) and increasing the hydrophilicity of the surface.
  • the hydrophilizing agent may be hydrophilic polymers. These are polymers which have hydrophilic groups. Examples of suitable hydrophilic groups are hydroxy, amino, carboxy, sulfonate. Further, the hydrophilic polymer usable for the preparation of the intermediate preferably has a number-average molecular weight of 1,000 to 500,000 g / mol, more preferably 2,000 to 50,000 g / mol. When the polymer used as the hydrophilizing agent is dissolved in water in an amount of 2% by weight, the resulting solution preferably exhibits a viscosity of 1 to 20 mPas, more preferably 1 to 5 mPas, still more preferably 2 to 4 mPas determined at 25 0 C and in accordance with Ph. Eur., 6th edition, chapter 2.2.10.
  • the hydrophilizing agent also comprises solid, non-polymeric compounds which preferably have polar side groups. Examples of these are sugar alcohols or disaccharides.
  • the intermediate according to the invention may comprise, for example, the following hydrophilic polymers as hydrophilizing agents: polysaccharides, such as hydroxypropylmethylcellulose (HPMC), carboxymethylcellulose (CMC, in particular sodium and calcium salts), ethylcellulose, methylcellulose, hydroxyethylcellulose, ethylhydroxyethylcellulose, hydroxypropylcellulose (HPC), microcrystalline cellulose ; Polyvinylpyrrolidone, polyvinyl alcohol, polymers of acrylic acid and salts thereof, polyacrylamide, polymethacrylates, vinylpyrrolidone-vinyl acetate copolymers (beispiels- as Kollidon ® VA64, BASF), polyoxyethylene / polyoxypropylene block polymer (poloxamer ®), gelatin, poly-alkylene glycols such as polypropylene glycol or, preferably, Polyethylene glycol, and mixtures thereof.
  • hydrophilic polymers as hydrophilizing agents: polysaccharides, such as
  • sugar alcohols and / or disaccharides such as mannitol, sorbitol, xylitol, isomalt, sucrose, lactose, glucose, fructose, maltose and mixtures thereof.
  • sugar alcohols here also includes monosaccharides.
  • hydrophilizing agents can generally be classified by changing the particle shape under pressing pressure (compression): plastic hydrophilicizing agents are characterized by plastic deformation, while brittle auxiliaries, under the action of a pressing force, break the particles into smaller particles. A brittle behavior of the hydrophilizing agent can be quantified by increasing the surface area in one pressing. In the art, it is common to classify brittleness by the so-called “yield pressure". According to a simple classification, the values for the "yield pressure" are small for plastic substances, but large for brittle substances [Duberg, M., Nyström, C, 1982.
  • the "yield pressure" will be determined from the reciprocal of the slope of the Heckel plot, as described in York, P., Drug Dev. Ind. Pharm. 18, 677 (1992).
  • the measurement is preferably carried out according to the "ejected tablet” method at 25 0 C and a deformation rate of 0, 1 mm / s.
  • a hydrophilicizing agent is considered to be a brittle hydrophilicizing agent if it has a yield pressure of at least 80 MPa, preferably 90 to 300 MPa.
  • brittle hydrophilicizing agents are microcrystalline cellulose, lactose and sucrose.
  • the intermediate of the invention contains micronized ambrisentan and hydrophilizing agent, wherein the weight ratio of micronised ambrisentan to hydrophilizing agent is 50: 1 to 1: 5, more preferably 20: 1 to 1: 1, even more preferably 15: 1 to 2: 1 especially 15: 1 to 5: 1.
  • the type and amount of the hydrophilizing agent be chosen so that at least 50% of the surface of the resulting intermediate particles are covered with hydrophilizing agent, more preferably at least 60% of the surface, more preferably at least 80% of the surface, especially at least 95% of the surface ,
  • the intermediate according to the invention may comprise, instead of or preferably in addition to the hydrophilizing agent, an emulsifier and / or pseudo-emulsifier.
  • the pseudo-emulsifiers explained in more detail below are preferably used.
  • the invention thus relates to a process for the preparation of the micronized ambrisentan or the intermediate according to the invention.
  • the intermediate of the invention contains micronized ambrisentan and hydrophilizing agent and / or pseudo-emulsifier, wherein the weight ratio of micronised ambrisentan to hydrophilizing agent and / or pseudo-emulsifier 50: 1 to 1: 5, more preferably 20: 1 to 1: 1, even more preferably 15: 1 to 2: 1, in particular 15: 1 to 5: 1.
  • Micronized ambrisentan according to the invention is usually obtainable by grinding.
  • the invention relates to a milling process for the preparation of the intermediate according to the invention, comprising the steps
  • Crystalline (non-micronized) ambrisentan and hydrophilizing agent are mixed in step (a1).
  • the mixture is ground in step (bl).
  • the mixing can be done before or during the milling, i. steps (a1) and (bl) can be done simultaneously.
  • the milling conditions are selected so that at least 50% of the surface area of the resulting intermediate particles is covered with hydrophilizing agent, more preferably at least 60% of the surface, more preferably at least 80% of the surface, especially at least 95% of the surface.
  • Milling is generally carried out in conventional grinding equipment, for example in a ball mill, air jet mill, pin mill, classifier mill, cross beater mill, disc mill, mortar mill, rotor mill.
  • An air jet mill is preferably used.
  • the meal is usually 0.5 minutes to 1 hour, preferably 2 minutes to 50 minutes, more preferably 5 minutes to 30 minutes.
  • the process conditions in this embodiment are preferably selected such that the resulting intermediate particles have a volume average particle diameter (D 50 ) of from 0.1 to 250 ⁇ m, more preferably from 0.5 to 50 ⁇ m, in particular from 1 to 25 ⁇ m or from 1 ⁇ m to 20 microns have.
  • the present inventors have found that the objects underlying the invention in an alternative embodiment can also be achieved by an intermediate containing micronized ambrisentan, optionally in combination with ambrisentan in the form of a solid solution, and hydrophilizing agent.
  • the invention thus relates to a process for the preparation of the intermediate containing ambrisentan in micronized form (and optionally partially in the form of a solid solution) and a hydrophilizing agent.
  • the preparation is preferably carried out by a so-called "pellet layering".
  • the invention thus relates to a method comprising the steps
  • step (a2) suspending the crystalline ambrisentene and the hydrophilizing agent in a solvent or solvent mixture, and (b2) spraying the suspension of step (a2) onto a carrier core.
  • step (a2) ambrisentan and the hydrophilizing agent described above are suspended in a solvent or solvent mixture, i. Ambrisentan leads at least partially in crystalline form.
  • Suitable solvents are e.g. Water, alcohol (e.g., methanol, ethanol, isopropanol), dimethyl sulfoxide (DMSO), acetone, butanol, ethyl acetate, heptane, pentanol, the mixtures thereof.
  • DMSO dimethyl sulfoxide
  • acetone butanol, ethyl acetate, heptane, pentanol, the mixtures thereof.
  • a mixture of water and DMSO is used.
  • Suitable hydrophilicizing agents in this alternative embodiment are in particular modified celluloses such as HPMC, sugar alcohols such as mannitol and sorbitol and polyethylene glycol, in particular polyethylene glycol having a molecular weight of from 2,000 to 10,000 g / mol.
  • step (b2) the suspension of step (a2) is sprayed onto a carrier core.
  • Suitable carrier cores are particles consisting of pharmaceutically compatible excipients, in particular so-called “neutral pellets”. Pellets are preferably used, which are available under the trade name Cellets ® and contain microcrystalline cellulose.
  • step (b2) takes place in a fluidized-bed dryer, for example in a Glatt GPCG 3 (Glatt GmbH, Germany).
  • the process conditions in this second embodiment are preferably selected such that the resulting intermediate particles have a volume-average particle diameter (D 50 ) of 50 to 750 ⁇ m, more preferably of 100 to 500 ⁇ m.
  • micronized ambrisentan according to the invention and the intermediate according to the invention are usually used for the preparation of a pharmaceutical formulation.
  • the invention therefore relates to a pharmaceutical formulation comprising micronized ambrisentan according to the invention or intermediate according to the invention and pharmaceutical auxiliaries.
  • auxiliaries used are disintegrants, release agents, emulsifiers, pseudo-emulsifiers, fillers, additives to improve the powder flowability, lubricants, wetting agents, gelling agents and / or lubricants.
  • the ratio of active ingredient to auxiliaries is preferably chosen so that the resulting formulations
  • the amount of active ingredient refers to the amount of micronized ambrisentan contained in the intermediate. It has been shown that a targeted choice of the disintegrant solves the tasks described above particularly preferably.
  • the pharmaceutical formulation according to the invention contains
  • the pharmaceutical formulation preferably contains one or more of the abovementioned excipients.
  • disintegrants are generally referred to substances that accelerate the disintegration of a dosage form, in particular a tablet, after being introduced into water.
  • Suitable disintegrants are e.g. organic disintegrants such as carrageenan, croscarmellose, sodium carboxymethyl starch and crospovidone.
  • alkaline disintegrants are meant disintegrating agents which when dissolved in water produce a pH of more than 7.0.
  • inorganic alkaline disintegrants are used, especially salts of alkali and alkaline earth metals.
  • Preferred are sodium, potassium, magnesium and calcium.
  • As anions carbonate, bicarbonate, phosphate, hydrogen phosphate and dihydrogen phosphate are preferred. Examples are sodium hydrogencarbonate, sodium hydrogenphosphate, calcium hydrogencarbonate and the like.
  • Crospovidone and / or croscarmellose are particularly preferably used as disintegrating agents, in particular in the abovementioned amounts.
  • the pharmaceutical formulation additionally contains
  • (Iii) release agent preferably in an amount of 0.1 to 5 wt .-%, more preferably 0.5 to 3 wt .-%, based on the total weight of the formulation.
  • Release agent (iii) is particularly important when the micronized ambrisentan is used as the intermediate of the invention.
  • release agents are usually understood substances which reduce the agglomeration in the core bed. Examples are talc, silica gel, polyethylene glycol (preferably with 2000 to 10,000 g / mol weight average molecular weight) and / or glycerol monostearate. Examples of preferred release agents are talc and polyethylene glycol (Mg 3000-6000 g / mol), carrageenan.
  • the pharmaceutical formulation additionally contains a
  • Pseudo-emulsifier preferably in an amount of 0, 1 to 5 wt .-%, more preferably 0.5 to 3 wt .-%, based on the total weight of the formulation.
  • Pseudo-emulsifiers are usually (preferably polymeric) substances which, when added to a solution, increase the viscosity of this solution.
  • the addition of 5% by weight of pseudo-emulsifier to distilled water at 20 ° C. preferably leads to an increase in the viscosity of at least 1%, preferably at least 2%, in particular at least 5%.
  • plant gums are preferably used.
  • Plant gums are polysaccharides of natural origin which cause the above viscosity increase.
  • pseudo-emulsifiers examples include agar, alginic acid, alginate, chicle, dammar, marshmallow extracts, gellan (E 418), guar gum (E 412), gum arabic (E 414), maple gum gum, spruce juice gum, locust bean gum E 410 ), Karaya (E 416), konjac flour (E 425), obtained from the konjac root, tara gum (E 417), tragacanth (E 413), xanthan (E 415), preferably produced by bacterial fermentation, and / or lecithin.
  • agar alginic acid, alginate, chicle, dammar, marshmallow extracts, gellan (E 418), guar gum (E 412), gum arabic (E 414), maple gum gum, spruce juice gum, locust bean gum E 410 ), Karaya (E 416), konjac flour (E 425), obtained from the konjac root, tara gum (E 417), tragacanth (
  • Possible emulsifiers are anionic emulsifiers, for example soaps, preferably alkali salts of higher fatty acids. Salts of bile acid (alkali metal salts); cationic emulsifiers, eg benzalkonium chloride, cetylpyridinium chloride, cetrimide; nonionic emulsifiers, for example, sorbitan derivatives, in particular sorbitan monolaurate, polyoxyethylene (20) sorbitan monolaurate, polyethylene glycol derivatives / polyoxyethylene derivative, especially polyoxyethylene (20) sorbitan monostearate, polyoxyethylene stearate, polyoxyethylene stearyl ether.
  • anionic emulsifiers for example soaps, preferably alkali salts of higher fatty acids. Salts of bile acid (alkali metal salts); cationic emulsifiers, eg benzalkonium chloride, cetylpyridinium chloride, cetrimide;
  • partial fatty acid esters of polyhydric alcohols for example glycerol monostearate, fatty acid esters of sucrose, fatty acid esters of polyglycol or casein.
  • partial fatty acid esters of polyhydric alcohols for example glycerol monostearate, fatty acid esters of sucrose, fatty acid esters of polyglycol or casein.
  • mixtures of the substances mentioned can be used.
  • the formulation according to the invention may also comprise further abovementioned pharmaceutical auxiliaries. These are explained in more detail below.
  • the formulation according to the invention preferably contains fillers.
  • Fillers are generally to be understood as meaning substances which serve to form the tablet body in the case of tablets with small amounts of active ingredient (for example less than 70% by weight). That is, fillers produce by "stretching" of the active ingredients sufficient Tablettiermassse. So fillers are usually used to obtain a suitable tablet size.
  • Examples of preferred fillers are lactose, lactose derivatives, starch, starch derivatives, treated starch, talc, chitin, cellulose and derivatives thereof, calcium phosphate, sucrose, calcium carbonate, magnesium carbonate, magnesium oxide, maltodextrin, calcium sulfate, dextrates, dextrin, dextrose, hydrogenated vegetable oil, kaolin, Sodium chloride, and / or potassium chloride. Also Prosolv® ® (Rettenmaier & Söhne, Germany) can be used.
  • Fillers are usually used in an amount of from 1 to 80% by weight, more preferably from 30 to 60% by weight, based on the total weight of the formulation.
  • silica such as known under the trade name Aerosil ®. Preference is given to using silica having a specific surface area of from 50 to 400 m 2 / g, determined by gas adsorption in accordance with Ph. Eur., 6th edition, Sept. 2, 1966.
  • Additives to improve the powder flowability are usually used in an amount of 0.1 to 3% by weight, based on the total weight of the formulation.
  • Lubricants can be used.
  • Lubricants are generally used to reduce sliding friction.
  • the sliding friction is to be reduced, which consists during tabletting on the one hand between the up in the die bore and from moving punches and the die wall and on the other hand between the tablet web and die wall.
  • Suitable lubricants are e.g. Stearic acid, adipic acid, sodium stearyl fumarate and / or magnesium stearate.
  • Lubricants are usually used in an amount of 0.1 to 3% by weight, based on the total weight of the formulation. It is in the nature of pharmaceutical excipients that they partially perform multiple functions in a pharmaceutical formulation.
  • the unambiguous delimitation is therefore preferably based on the fiction that a substance which is used as a specific excipient is not simultaneously used as a further pharmaceutical excipient.
  • PEG 4000 - if used as a hydrophilizing agent - not additionally used as a release agent (although PEG 4000 also shows a release effect).
  • microcrystalline cellulose - if used as a hydrophilicizing agent - not additionally used as a disintegrating agent (although microcrystalline cellulose also shows a certain explosive effect).
  • the pharmaceutical formulation of the invention is preferably compressed into tablets.
  • the prior art proposes direct compression of ambrisentan formulation (see EMEA Assessment Report for Volibris, 2008, Procedure No. EMEA / H / C / 000839).
  • the properties of the resulting tablets can be improved if the pharmaceutical formulation according to the invention is subjected to wet granulation or suspension granulation before being pressed into the tablet.
  • the subject of the present invention is therefore a method comprising the steps
  • step (II) wetting or suspending the substances from step (I) with, or in a granulating solution
  • step (I) ambrisentan or the intermediate according to the invention and pharmaceutical excipients are provided.
  • the pharmaceutical excipients are preferably the adjuvants described above.
  • the substances are preferably mixed.
  • the mixing can be done in conventional mixers. To ensure a uniform distribution, mixing in so-called intensive mixers is preferred. For example, the mixing can take place in compulsory mixers or free-fall mixers. Alternatively, mixing may occur during steps (II) and (III).
  • the substances from step (I) are moistened with a granulating liquid or are suspended in a granulating liquid.
  • Suitable granulating liquids are, for example, water, alcohols and mixtures thereof. Preference is given to a mixture of water and ethanol.
  • steps (I) to (IV) can be carried out in conventional granulation. Preference is given here to the “one-pot process” or the “fluidized-bed process”.
  • step (I) the substances from step (I) are moistened with granulating liquid and granulated.
  • the steps (II) and (III) are preferably carried out at the same time.
  • the granules are then dried and optionally sieved.
  • a suitable granulating machine is e.g. Diosna Pl / 6.
  • the substances from step (I) are suspended in granulation liquid and sprayed to dryness. Mixing, moistening, granulating and drying are done in one go. The granules are optionally subsequently sieved.
  • a suitable fluidized bed apparatus is e.g. Smooth GPCG 3.
  • the granulation conditions are selected such that the resulting particles (granules) have a volume average particle size (d 50 value) of 50 to 600 microns, more preferably 100 to 500 microns, even more preferably 150 to 400 microns, especially from 200 to 350 ⁇ m.
  • d 50 value volume average particle size
  • the granulation conditions are preferably selected so that the resulting granules have a bulk density of 0.2 to 0.85 g / ml, more preferably 0.3 to 0.8 g / ml, especially 0.4 to 0.7 g / ml exhibit.
  • the Hausner factor is usually in the range of 1, 03 to 1, 3, more preferably from 1, 04 to 1, 20 and in particular from 1, 04 to 1, 15. In this case, "Hausner factor" is the ratio of tamped density understood to bulk density.
  • the resulting from step (IV) granules can be processed into pharmaceutical dosage forms.
  • the granules are filled, for example, in sachets or capsules.
  • the granulate resulting from step (IV) is preferred compressed into tablets.
  • the pressing step (V) will be described below.
  • the invention thus relates to tablets obtainable by compression of a granulate obtained from step (IV).
  • step (V) of the process the granules obtained in step (IV) are compressed into tablets, i. There is a compression to tablets.
  • the compression can be done with tableting machines known in the art.
  • step (V) of the process pharmaceutical excipients may optionally be added to the granules of step (IV).
  • step (V) usually depend on the type of tablet to be prepared and on the amount of excipients already added in step (I).
  • the powder flowability improving additives and lubricants described above are used.
  • the tablets produced by the process according to the invention may be tablets which are swallowed whole (unfiltered or preferably film-coated). It can also be chewable tablets or disperse tablets.
  • Disperse tablets is here understood to mean a tablet for the production of an aqueous suspension for oral use.
  • the tabletting conditions are preferably chosen so that the resulting tablets have a tablet height to weight ratio of 0.005 to 0.3 mm / mg, more preferably 0.05 to 0.2 mm / mg.
  • the resulting tablets preferably have a hardness of 35 or 50 to 200 N, more preferably from 40 to 100 N or 80 to 150 N. Hardness is calculated according to Ph.Eur. 6.0, section 2.9.8.
  • the resulting tablets preferably have a friability of less than 10%, particularly preferably less than 8%.
  • the friability is calculated according to Ph.Eur. 6.0, Section 2.9.7.
  • the tablets according to the invention usually have a "content uniformity" of 85 to 15% of the average content, preferably 90 to 110%, in particular 95 to 105% of the average content.
  • the "Content Uniformity” is according to Ph. Eur.6.0, Section 2.9.6. certainly.
  • the release profile of the tablets according to the invention usually has a released content of at least 30%, preferably at least 50%, in particular at least 70%, according to the USP method after 10 minutes.
  • the above information on hardness, friability, content uniformity and release profile in this case relate preferably to the uninfiltrated tablet.
  • the pharmaceutical formulation according to the invention in addition to the preferred wet granulation described above, it is alternatively also possible for the pharmaceutical formulation according to the invention to be subjected to dry granulation before being pressed into the tablet.
  • the subject of the present invention is therefore alternatively a method comprising the steps
  • (I-T) providing the micronized ambrisentan or the intermediate according to the invention and one or more pharmaceutical excipients (especially those described above);
  • (II-T) Compaction into a scab; and
  • ambrisentan and adjuvants are preferably mixed.
  • the mixing can be done in conventional mixers.
  • the micronized and preferably hydrophilized ambrisentan is first mixed with only part of the auxiliaries (eg 50 to 95%) before compaction (II), and that the remaining part of the excipients after the granulation step (III-T) is added.
  • the admixing of the excipients should preferably take place before the first compaction step, between several compaction steps or after the last granulation step.
  • step (II-T) of the alternative method of the invention the mixture of step (IT) is compacted into a slug. It is preferred that this is a dry compaction, ie the compaction is preferably carried out in the absence of solvents, in particular in the absence of organic solvents.
  • the compaction conditions in step (HT) are preferably chosen such that the slug has a density of 0.75-1.1 g / cm 3 .
  • the term “density” in this case preferably refers to the "true density” (ie not to the bulk density or tamped density) .
  • the purity can be determined using a gas pycnometer
  • the gas pycnometer is a helium pycnometer, in particular the device AccuPyc 1340 Helium pycnometer manufactured by Micromeritics, Germany.
  • the compaction is preferably carried out in a roll granulator.
  • the rolling force is 2 to 50 kN / cm, more preferably 4 to 30 kN / cm, especially 10 to 25 kN / cm.
  • the gap width of the rolling granulator is, for example, 0.8 to 5 mm, preferably 1 to 4 mm, more preferably 1, 5 to 3 mm, in particular 1, 8 to 2.8 mm.
  • the compacting device used preferably has a cooling device. In particular, it is cooled in such a way that the temperature of the compactate 50 0 C, in particular 40 0 C does not exceed.
  • step (III-T) of the process the slug is granulated.
  • the granulation can be carried out by methods known in the art.
  • the granulation conditions are selected such that the resulting particles (granules) have a volume average particle size (d 50 value) of 50 to 600 microns, more preferably 100 to 500 microns, even more preferably 150 to 400 microns, especially from 200 to 350 ⁇ m.
  • d 50 value volume average particle size
  • the granulation is carried out in a sieve mill.
  • the mesh size of the sieve insert is usually 0, 1 to 5 mm, preferably 0.5 to 3 mm, more preferably 0.75 to 2 mm, in particular 0.8 to 1.8 mm.
  • the process is adapted such that a multiple compaction takes place, wherein the granulate resulting from step (III-T) is recycled once or several times for compaction (H-T).
  • the granulate from step (III-T) is preferably recycled 1 to 5 times, in particular 2 to 3 times.
  • the granules resulting from step (III-T) can be processed into pharmaceutical forms of administration as described above for wet granulation.
  • the granules are filled, for example, in sachets or capsules.
  • the granules resulting from step (III-T) are compressed into tablets.
  • they In the case of tablets which are swallowed whole, it is preferred that they be coated with a film layer.
  • the usual in the prior art method for filming tablets can be used.
  • the above-mentioned ratios of active ingredient to excipient relate to the unpainted tablet.
  • macromolecular substances are used for the coating, for example modified celluloses, polymethacrylates, polyvinylpyrrolidone, polyvinyl acetate phthalate, zein and / or shellac.
  • HPMC in particular HPMC having a number average molecular weight of from 10,000 to 150,000 g / mol and / or an average degree of substitution of -OCH 3 groups of from 1.2 to 2.0.
  • the layer thickness of the coating is preferably 10 to 100 ⁇ m.
  • micronized drug was combined in water with 2 g of povidone / 4 g of Arabic
  • This suspension is for the granulation of 100 g of Avicel ®, 50 g
  • Lactose 20 g carboxymethyl starch used (Diosna P l).
  • the granulate was mixed with 1 g of Aerosil ®, 2 g of magnesium stearate and 30 g of Avicel ® to a tablet capable mixture in a free fall mixer together for an additional 5
  • the tablets had a hardness of 40 - 100 N, combined with a friability of less than 10%.
  • Example 2 Micronization and wet granulation
  • micronized drug was suspended in water along with 0.5 g of HPMC / 1 g of Arabic gum. This suspension was used to granulate 90 g of corn starch, 12 g of crospovidone (Diosna P l).
  • the tablets had a hardness of 40 - 100 N, combined with a friability of less than 10%.
  • the tablets were coated with 4 g HPMC (Pharmacoat ® 603), 0.5 g of titanium dioxide, 0.5 g talcum and 0.3 PEG in a drum coater (Lödige LHC 25) coated from aqueous solution.
  • Ambrisentan, Malsquest and PVP were granulated with water. The granules were dried at 40 ° C. for 60 minutes. Aerosil ®, corn starch and magnesium stearate were sieved through a 1000 .mu.m sieve, added to the granules and mixed for 3 minutes. Pruv ® was supplemented and mixed again. The mixture was compressed into tablets of 155 mg. The active substance content is 5 mg.
  • Ambrisentan and corn starch were mixed together in the Turbula TlOB mixer for 15 minutes at 32 rpm. Magnesium stearate was added and mixed for an additional 3 minutes. Then Prosolv® ® and Aerosil ® were added to improve the flowability. The mixture was pressed directly into tablets of 147 mg.
  • Ambrisentan, calcium bicarbonate and sodium carboxymethyl starch were weighed together and mixed for 15 minutes. Magnesium stearate was added and mixed for an additional 3 minutes. The mixture was pressed directly into tablets of 140 mg. The active ingredient content was 5 mg.
  • Microcelac ® (75% lactose monohydrate and 25% microcrystalline cellulose) 0.63 g Croscarmellose sodium 0.21 g magnesium stearate Ambrisentan, Microcelac ® and croscarmellose sodium were weighed together and mixed for 15 minutes. Magnesium stearate was added and mixed for an additional 3 minutes. The mixture was pressed directly into tablets of 140 mg. The active ingredient content was 5 mg.
  • Microcelac ® (75% lactose monohydrate and 25% microcrystalline cellulose) 0.63 g Croscarmellose sodium 0.21 g magnesium stearate
  • ambrisentan Microcelac ® were milled for 30 minutes at 350 rpm in a ball mill. To the mixture is added croscarmellose sodium and magnesium stearate and mixed for an additional 3 minutes. The mixture is pressed directly into tablets of 140 mg. The active substance content is 5 mg.
  • Ambrisentan and MCC were ball milled at 350 rpm for 30 minutes in a ball mill. To the mixture was added sodium carboxymethyl starch and calcium hydrogen phosphate and mixed for 10 minutes. Thereafter, magnesium stearate was added and mixed for an additional 3 minutes. The mixture was pressed directly into tablets of 140 mg. The active ingredient content was 5 mg.
  • Example 11 Micronization and wet granulation
  • Ambrisentan and MCC (part 1) were ball milled for 30 minutes at 350 rpm. From the milling, MCC (TeU 2) and PVP was a granules with
  • Calcium hydrogen phosphate, sodium carboxymethyl starch and magnesium stearate were sieved through a 1000 ⁇ m sieve, added to the granules and mixed for three minutes. The mixture was pressed into tablets of 140 mg. The active ingredient content was 5 mg.
  • Example 12 Micronization and wet granulation
  • Ambrisentan and MCC (TeU 1) were ball milled for 30 minutes at 350 rpm. From the milling a suspension was prepared with water. This was sprayed onto MCC (TeU 2) and PVP and granules made.
  • Granules were dried at 40 0 C overnight. AerosU ®, calcium hydrogen phosphate, sodium carboxymethyl starch and magnesium stearate were a 1000 .mu.m sieve sieved, added to the granules and mixed for 3 minutes. The mixture was compressed into tablets of 140 mg. The active ingredient content was 5 mg.

Abstract

L’invention concerne des formulations pharmaceutiques pour la réduction de la pression artérielle pulmonaire, qui contiennent de l’Ambrisentan micronisé, de préférence sous la forme d’un intermédiaire, accompagné d’un agent d’hydrophylisation. L’invention concerne également des procédés de fabrication de formulations pharmaceutiques, qui contiennent de l’Ambrisentan micronisé.
EP09777743A 2008-08-11 2009-08-07 Formulation pharmaceutique pour la réduction de la pression artérielle pulmonaire Withdrawn EP2309995A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008037324A DE102008037324A1 (de) 2008-08-11 2008-08-11 Pharmazeutische Formulierung zur pulmonalen Blutdrucksenkung
PCT/EP2009/005749 WO2010017917A1 (fr) 2008-08-11 2009-08-07 Formulation pharmaceutique pour la réduction de la pression artérielle pulmonaire

Publications (1)

Publication Number Publication Date
EP2309995A1 true EP2309995A1 (fr) 2011-04-20

Family

ID=41213450

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09777743A Withdrawn EP2309995A1 (fr) 2008-08-11 2009-08-07 Formulation pharmaceutique pour la réduction de la pression artérielle pulmonaire

Country Status (5)

Country Link
US (1) US20110189243A1 (fr)
EP (1) EP2309995A1 (fr)
CA (1) CA2733651A1 (fr)
DE (1) DE102008037324A1 (fr)
WO (1) WO2010017917A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA026094B1 (ru) 2009-12-23 2017-03-31 Рациофарм Гмбх Твердая лекарственная форма тикагрелора
CN103919747A (zh) * 2014-04-22 2014-07-16 天津红日药业股份有限公司 一种安立生坦片剂组合物及其制备方法
CN105581990A (zh) * 2014-08-27 2016-05-18 人福医药集团股份公司 安立生坦片剂及其制备方法
CN104382840A (zh) * 2014-10-09 2015-03-04 南京泽恒医药技术开发有限公司 S-安立生坦口服组合物及制备方法
CN109276546A (zh) * 2018-10-07 2019-01-29 威海贯标信息科技有限公司 一种安立生坦片剂组合物
CN109320463A (zh) * 2018-10-07 2019-02-12 威海贯标信息科技有限公司 一种小粒度安立生坦的纯化方法
CN109320464A (zh) * 2018-10-07 2019-02-12 威海贯标信息科技有限公司 一种小粒度安立生坦的纯化方法
CN110025587A (zh) * 2019-04-28 2019-07-19 常州恒邦药业有限公司 安立生坦口服片剂及其制备方法
TR202020618A2 (tr) * 2020-12-16 2022-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Mi̇kroni̇ze ambri̇sentan i̇çeren bi̇r fi̇lm kapli tablet

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489026A (en) * 1982-09-07 1984-12-18 The Upjohn Company Process for preparing solid unit dosage forms of ultra-low dose drugs
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
AR016827A1 (es) * 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
CN101090714A (zh) * 2004-07-26 2007-12-19 康泽里克斯公司 通过吸入伊洛前列素和微粒制剂治疗肺动脉高血压症
EP2118073A2 (fr) * 2007-02-02 2009-11-18 Concert Pharmaceuticals Inc. Antagonistes sélectifs des récepteurs de type a de l'endothéline

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EUROPEAN MEDICINES AGENCY (EMEA): "Assessment Report for Volibris", 1 April 2008 (2008-04-01), pages 1 - 44, XP055211575 *
See also references of WO2010017917A1 *

Also Published As

Publication number Publication date
CA2733651A1 (fr) 2010-02-18
WO2010017917A1 (fr) 2010-02-18
US20110189243A1 (en) 2011-08-04
DE102008037324A1 (de) 2010-02-18

Similar Documents

Publication Publication Date Title
DE69434640T2 (de) Heterodisperse Hydrogelsysteme zur verzögerten Freisetzung unlöslicher Arzneistoffe
EP2309995A1 (fr) Formulation pharmaceutique pour la réduction de la pression artérielle pulmonaire
EP2334284B1 (fr) Cinacalcet compacté
EP2355802A1 (fr) Produits intermédiaires et formes galéniques orales contenant de la lénalidomide
EP2364141B2 (fr) Moxifloxacine compactée
DE102009015702A1 (de) Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung
WO2011076412A1 (fr) Forme d'administration orale contenant de l'entecavir
EP2309996A2 (fr) Ambrisentan amorphe
EP2415460A1 (fr) Formulations pour l'administration orale de prégabaline
DE102009013611A1 (de) Festes Retigabin in nicht-kristalliner Form
WO2012010669A2 (fr) Médicament d'administration orale contenant un mélange de silodosine et d'un copolymère basique
WO2010043408A2 (fr) Fésotérodine microencapsulée
EP2490674A2 (fr) Cinacalcet granulé par fusion
DE102008057284A1 (de) Tabletten enthaltend Lenalidomid und Adhäsionsverstärker
WO2009056266A2 (fr) Candesartan cilexetil
WO2010105822A2 (fr) Transformation à sec de rétigabine
WO2011076411A1 (fr) Comprimé dispersible par voie orale contenant une base de sildénafil compactée
WO2011138037A2 (fr) Tapentadol solide sous forme non cristalline
EP2416761A1 (fr) Desfésotérodine sous forme de sel d'acide tartrique
EP2445484A1 (fr) Aprépitant sous forme de solution solide
DE102008057285A1 (de) 3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidindion in Form einer festen Lösung
EP2382967A1 (fr) Aliskiren sous forme d'une dispersion solide
DE102009060194A1 (de) Orale Darreichungsform umfassend Entecavir
DE102008057335A1 (de) Amorphes Lenalidomid

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110121

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KOTSCHENREUTHER, DUNJA

Inventor name: PAETZ, JANA

Inventor name: BRUECK, SANDRA

Inventor name: MUSKULUS, FRANK

Inventor name: RIMKUS, KATRIN

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: RATIOPHARM GMBH

17Q First examination report despatched

Effective date: 20150911

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160322